Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. (Q39699164)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Michael Toole

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Joseph Merriman

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Kinjal Parikh

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sarah Scarlett

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Peg Esper

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Katherine Skinner

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Aaron Udager

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Srinivas Kiran Tantravahi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

David Gill

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Alli M Straubhar

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Archana M Agarwal

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Kenneth F Grossmann

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Wolfram E Samlowski

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Bruce Redman

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Neeraj Agarwal

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Ajjai Alva

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

65

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

941-949

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Recent developments in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

The role of interleukin-2 during homeostasis and activation of the immune system

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Kidney cancer, version 3.2015.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1854-1

21 January 2018

Identifiers

10.1007/S00262-016-1854-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27277816%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39699164&oldid=2203101799"